ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function

Blood

Volumn 113, Issue 10, 2009, Pages 2181-2190

  Collins, Natalie B ^a   Wilson, James B ^b   Bush, Thomas ^c   Thomashevski, Andrei ^c   Roberts, Kate J ^b   Jones, Nigel J ^b   Kupfer, Gary M ^c,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LMP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; DNA; FANCONI ANEMIA GROUP A PROTEIN; PHOSPHOPEPTIDE; SERINE;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; FANCONI ANEMIA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MUTANT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION;

EID: 64049107302     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-154294     Document Type: Article

References (50)

1. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer. 2003;97:425-440.
2. Kutler DI, Singh B, Satagopan J, et al. A20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.
3. McGowan CH, Russell P. The DNAdamage response: sensing and signaling. Curr Opin Cell Biol. 2004;16:629-633.
4. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107:4223-4233.
5. Collins N, Kupfer GM. Molecular pathogenesis of Fanconi anemia. Int J Hematol. 2005;82:176-183.
6. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-457.
7. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162-164.
8. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159-161.
9. Thomashevski A, High AA, Drozd M, et al. The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments. J Biol Chem. 2004;279:26201-26209.
10. Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet. 2004;36:1219-1224.
11. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35:165-170.
12. Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet. 2005;37:958-963.
13. Ciccia A, Ling C, Coulthard R, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell. 2007; 25:331-343.
14. Ling C, Ishiai M, Ali AM, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 2007;26:2104-2114.
15. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7: 249-262.
16. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'AndreaAD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 2002; 100:2414-2420.
17. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a mono-ubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129:289-301.
18. Naf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD. Functional activity of the fanconi anemia protein FAC requires FAC binding and nuclear localization. Mol Cell Biol. 1998;18:5952-5960.
19. Matsushita N, Kitao H, Ishiai M, et al. A FancD2-mono-ubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol Cell. 2005;19:841-847.
20. Qiao F, Mi J, Wilson JB, et al. Phosphorylation of fanconi anemia complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. J Biol Chem. 2004;279:46035-46045.
21. Kupfer G, Naf D, Garcia-Higuera I, et al. A patient-derived mutant form of the Fanconi anemia protein, FANCA, is defective in nuclear accumulation. Exp Hematol. 1999;27:587-593.
22. Mi J, Qiao F, Wilson JB, et al. FANCG is phos-phorylated at serines 383 and 387 during mitosis. Mol Cell Biol. 2004;24:8576-8585.
23. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the fanconi anemia and ataxiatelangiecta-sia signaling pathways. Cell. 2002;109:459-472.
24. Ho GP, Margossian S, Taniguchi T, D'AndreaAD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol. 2006;26:7005-7015.
25. Wang X, Kennedy R, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol. 2007;12:12.
26. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M. DNAreplication is required Toelicit cellular responses to psoralen-induced DNAinterstrand cross-links. Mol Cell Biol. 2000;20:8283-8289.
27. Wang X, D'Andrea AD. The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair (Amst). 2004;3:1063-1069.
28. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 mono-ubiquitination to the DNA-damage response. Genes Dev. 2004;18:1958-1963.
29. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. Asplicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet. 2003;33:497-501.
30. Yagasaki H, Adachi D, Oda T, et al. Acytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA. Blood. 2001;98: 3650-3657.
31. Adachi D, Oda T, Yagasaki H, et al. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. Hum Mol Genet. 2002;11:3125-3134.
32. Kupfer GM, Naf D, Suliman A, Pulsipher M, D'Andrea AD. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nat Genet. 1997;17:487-490.
33. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996;93: 11400-11406.
34. Qiao F, Moss A, Kupfer GM. Fanconi anemia proteins localize to chromatin and the nuclear matrix in a DNA damage-and cell cycle-regulated manner. J Biol Chem. 2001;276:23391-23396.
35. Wilson JB, Yamamoto K, Marriott AS, et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene. 2008;27:3641-3652.
36. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia mono-ubiquitination pathway promotes homologous DNA repair. Proc Natl AcadSciU S A. 2005;102:1110-1115.
37. YamashitaT, Kupfer GM, Naf D, et al.Thefanconi anemia pathwayrequires FAAphosphoryla-tion and FAA/FAC nuclear accumulation. Proc Natl Acad Sci USA. 1998;95:13085-13090.
38. SchonthalAH. Role of PP2A in intracellular signal transduction pathways. Front Biosci. 1998;3: D1262-D1273.
39. O'Neill T, Dwyer AJ, Ziv Y, et al. Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem. 2000;275:22719-22727.
40. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160-1166.
41. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
42. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 2004; 23:1178-1187.
43. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phospho-inositide 3-kinase related kinases by the radio-sensitizing agent wortmannin. Cancer Res. 1998; 58:4375-4382.
44. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37:934-935.
45. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005;8:255-265.
46. Itakura E, Umeda K, Sekoguchi E, Takata H, Ohsumi M, Matsuura A. ATR-dependent phos-phorylation of ATRIP in response to genotoxic stress. Biochem Biophys Res Commun. 2004;323:1197-1202.
47. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433-439.
48. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNAdamage. Cancer Res. 2000;60:566-572.
49. Mi J, Kupfer GM. The Fanconi anemia core complex associates with chromatin during S phase. Blood. 2005;105:759-766.
50. Nijman SM, Huang TT, Dirac AM, et al. The deu-biquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005;17:331-339.